Welcome to our dedicated page for Rocket Pharmaceu SEC filings (Ticker: RCKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rocket Pharmaceuticals’ 10-K isn’t just numbers—it’s 250+ pages of gene-therapy science, trial protocols and dilution math that can overwhelm even seasoned analysts. If you’re trying to pinpoint when a lentiviral program moves from Phase 1 to Phase 2, trace cash-burn trends, or monitor executive stock sales, traditional SEC readers make the search slow. That complexity is exactly why our AI-powered Stock Titan hub exists.
Every submission—from a Rocket Pharmaceuticals quarterly earnings report 10-Q filing to the next Rocket Pharmaceuticals 8-K material events explained—appears here seconds after hitting EDGAR. Our engine produces plain-English summaries, highlights trial-related risk factors and surfaces critical numbers. Need governance details? The Rocket Pharmaceuticals proxy statement executive compensation section is broken down so you see option grants alongside milestone-based bonuses. Tracking insider sentiment? Receive alerts for Rocket Pharmaceuticals insider trading Form 4 transactions and view Rocket Pharmaceuticals Form 4 insider transactions real-time. Key filing insights include:
- Pipeline spend vs. runway in every Rocket Pharmaceuticals annual report 10-K simplified
- Sequential data on trial enrollment from each 10-Q earnings update
- Cash-raising shelf registrations flagged within S-3 filings
- Director buys and sells via Rocket Pharmaceuticals executive stock transactions Form 4
- Partnership or FDA feedback disclosed through 8-K items
With AI-generated redline comparisons and exportable tables, understanding Rocket Pharmaceuticals SEC documents with AI becomes practical—not a weekend project. Use our concise Rocket Pharmaceuticals earnings report filing analysis to gauge milestone catalysts, or set custom watchlists so you never miss the next data-driven move. Complex biotech filings, clarified and delivered in real time.
Rocket Pharmaceuticals disclosure shows that Maverick-affiliated entities and Lee S. Ainslie beneficially hold 8,363,813 shares of common stock, equal to 7.8% of the company based on 107,737,919 shares outstanding. The reported holdings arise from multiple funds and accounts: Maverick Fund USA, Ltd. (1,686,548 shares); Maverick Fund II, Ltd. (1,727,675); Maverick Long Enhanced Fund, Ltd. (1,930,078); Maverick HP, L.P. (1,726,954); Maverick Long Fund, Ltd. (958,547); and separately managed accounts (334,011).
Maverick is identified as the investment adviser with investment discretion over these client accounts, Maverick Capital Management is the general partner, and Lee S. Ainslie III is the manager. The filing reports no sole voting or dispositive power and shared voting and dispositive power over all 8,363,813 shares, indicating a significant institutional stake without unilateral control.
Item 2.02: On August 7, 2025 Rocket Pharmaceuticals, Inc. announced preliminary financial information for the quarter ended June 30, 2025 via a press release furnished as Exhibit 99.1. The filing states the exhibit is furnished, not filed under Item 2.02 and therefore not subject to Section 18 liability.
Item 5.02: Effective December 31, 2025, Dr. Kinnari Patel will leave the Company to join RTW Investments LP as a venture partner. As of August 8, 2025 she no longer serves as President, Head of Research and Development and will assist in transitioning her duties to other executives. Exhibits include the press release (99.1) and Inline XBRL cover page (104). The report is signed by Martin Wilson on August 7, 2025.
FAQ
What is the current stock price of Rocket Pharmaceu (RCKT)?
What is the market cap of Rocket Pharmaceu (RCKT)?
